Critical Analysis: Alliqua BioMedical (ALQA) and The Competition
Alliqua BioMedical (NASDAQ: ALQA) is one of 91 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare Alliqua BioMedical to related companies based on the strength of its institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and risk.
Institutional & Insider Ownership
66.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 15.8% of Alliqua BioMedical shares are owned by insiders. Comparatively, 11.8% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of recent ratings and price targets for Alliqua BioMedical and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alliqua BioMedical Competitors||197||1207||2643||92||2.64|
Alliqua BioMedical currently has a consensus target price of $14.17, indicating a potential upside of 284.96%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.92%. Given Alliqua BioMedical’s stronger consensus rating and higher possible upside, research analysts plainly believe Alliqua BioMedical is more favorable than its competitors.
This table compares Alliqua BioMedical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alliqua BioMedical Competitors||-124.64%||-36.13%||-9.58%|
Risk and Volatility
Alliqua BioMedical has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Alliqua BioMedical’s competitors have a beta of 1.11, meaning that their average stock price is 11% more volatile than the S&P 500.
Earnings & Valuation
This table compares Alliqua BioMedical and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Alliqua BioMedical||$18.24 million||-$28.24 million||-0.30|
|Alliqua BioMedical Competitors||$1.05 billion||$129.96 million||205.80|
Alliqua BioMedical’s competitors have higher revenue and earnings than Alliqua BioMedical. Alliqua BioMedical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Alliqua BioMedical competitors beat Alliqua BioMedical on 8 of the 12 factors compared.
Alliqua BioMedical Company Profile
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers SilverSeal.
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.